Argenx won FDA approval for second indication of Vyvgart for CIDP in June. Currently, Vyvgart dominates gMG treatment market. Competitor's drug filing for gMG raises the competition risk.
What is covered in the Full Insight:
Introduction and Background
Vyvgart's Market Position and Performance
Competitive Landscape
Pipeline Developments and Future Prospects
Financial Performance and Analyst Perspectives
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.